Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from AIM ImmunoTech ( (AIM) ) is now available.
On March 4, 2026, AIM ImmunoTech created a new Series G Convertible Preferred Stock, authorizing 12,000 shares with a $1,000 stated value each, initially convertible into common stock at $1.00 per share and subject to ownership caps between 4.99% and 9.99% to limit concentration. The preferred shares carry as-converted dividend and liquidation rights pari passu with common stock, no voting rights except as required by law, and no redemption obligations, positioning them as a flexible equity financing tool.
On March 6, 2026, the company completed a rights offering, selling 1,842 units consisting of 1,842 shares of Series G Preferred Stock and 3,684,000 Class G Warrants exercisable at $1.00 per share, raising approximately $1.8 million in gross proceeds. Concurrently, AIM ImmunoTech entered into a Warrant Agency Agreement with Equiniti Trust Company to administer the warrants, strengthening its capital structure and providing additional potential future equity funding via warrant exercises.
The most recent analyst rating on (AIM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
The score is primarily weighed down by very weak financial performance (large losses, negative equity, and ongoing cash burn). Technicals also remain unfavorable with a broader downtrend and negative MACD, while valuation is constrained by negative earnings and no dividend support. A recent corporate update further underscored significant development and funding/regulatory risks.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-therapeutic products, with its capital structure centered on common and preferred stock and related securities. The company accesses equity markets through instruments such as convertible preferred shares and warrants to fund its operations and advance its strategic objectives.
Average Trading Volume: 1,419,019
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.71M
See more insights into AIM stock on TipRanks’ Stock Analysis page.